Pharmacological Studies on Androgen Suppression in Therapy of Prostate Carcinoma

Sandow, J.; Rechenberg, W. von; Engelbart, K.

doi:10.1097/00000421-198812001-00002

Cited by 10 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Testosterone and adrenal androgens can be converted to dihydrotestosterone (DHT), a more potent hormone, within the cytoplasm of prostatic cells by the enzyme 5-alfa-reductase. 20 DHT binds to an androgen receptor within the cytosol, then translocates into the nucleus where it can affect gene synthesis, the production of proteins such as prostate-specific antigen (PSA), and cellular functions such as proliferation, growth, and cell death.…”

Section: Androgens and The Prostatementioning

confidence: 99%

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Sethi¹,

Sanfilippo²

2009

CIA

View full text Add to dashboard Cite

Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.

show abstract

Section: Androgens and The Prostatementioning

confidence: 99%

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Sethi¹,

Sanfilippo²

2009

CIA

View full text Add to dashboard Cite

show abstract

“…Although circulating testosterone is markedly decreased postoperatively, significant levels of prostatic dihydrotestosterone (DHT) (up to 40%) and testosterone (5 -10%), as well as adrenal androgens (> 50%), can be detected in the anorchic man [51][52][53]. Prior to the development of antiandrogen medications, bilateral adrenalectomy was the most commonly used way to completely deprive prostate cancer of androgens in patients who had disease progression after receiving castrative therapy [54] .…”

Section: Combined Androgen Blockadementioning

confidence: 99%

Androgen deprivation therapy for prostate cancer

Singer

Golijanin

Miyamoto

et al. 2008

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.Keywords: androgen deprivation , antiandrogen , combined androgen blockade , hormonal therapy , intermittant androgen deprivation , luteinizing hormone releasing hormone , prostate cancer , side effect Expert Opin. Pharmacother. (2008) 9(2):211-228

show abstract

“…Conversion occurs in the cytoplasm of prostatic cells by the enzyme 5-alfa reductase. In addition to testosterone, adrenal androgens may be converted to DHT (Sandow et al 1988). In the cytosol, DHT binds to the androgen receptor and crosses into the nucleus.…”

Section: Physiology: Hypothalamuspituitary -Testis Axismentioning

confidence: 99%

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Crawford¹

2008

TCRM

View full text Add to dashboard Cite

Hormone therapy is well established for treating patients with prostate cancer and remains the mainstay of the treatment of metastatic and locally advanced disease, this article reviews the rationale for its use, its different forms, and complications and controversies still surrounding some of its modalities. Availability of long-acting synthetic luteinizing hormonereleasing hormone (LHRH) agonists revolutionized the hormonal treatment of prostate cancer, and helped to avoid the emotional and psychological effects related to surgical castration. The depot formula has gained wide acceptance from both patients and physicians. This review emphasizes the newer, long-acting formula, leuprorelin (leuprolide acetate), especially the 6-month formula, its advantage over over shorter-acting depot products, and its potential to become a standard of care for patients eligible for androgen deprivation therapy.

show abstract

Pharmacological Studies on Androgen Suppression in Therapy of Prostate Carcinoma

Cited by 10 publications

References 0 publications

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer

Androgen deprivation therapy for prostate cancer

Leuprorelin depot injection: patient considerations in the management of prostatic cancer

Contact Info

Product

Resources

About